Unmet treatment needs remain in multiple myeloma, particularly among patients with relapsed/refractory disease who have received multiple lines of therapy. This study evaluates a potential salvage approach of daratumumab-based retreatment in patients refractory to daratumumab and/or pomalidomide.
Risk stratification tools are frequently used to help guide treatment decisions after first relapse in multiple myeloma. Researchers have developed a new risk stratification tool consisting of 4 distinct dimensions that is used to characterize survival expectations.
By prior treatment exposure, all subgroups in the CASTOR trial benefited from the addition of daratumumab to bortezomib/dexamethasone, including patients refractory to lenalidomide at last treatment.
Results 121 - 130 of 184